Zwj Investment Counsel Inc buys $17,851,848 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Zwj Investment Counsel Inc scooped up 3,977 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 224,354 shares of Gilead Sciences which is valued at $17,851,848.Gilead Sciences makes up approximately 1.79% of Zwj Investment Counsel Inc’s portfolio.

Other Hedge Funds, Including , Bailard boosted its stake in GILD in the latest quarter, The investment management firm added 24,110 additional shares and now holds a total of 27,769 shares of Gilead Sciences which is valued at $2,209,579. Gilead Sciences makes up approx 0.26% of Bailard’s portfolio. Jennison Associates sold out all of its stake in GILD during the most recent quarter. The investment firm sold 9,147 shares of GILD which is valued $732,583.1st Source Bank boosted its stake in GILD in the latest quarter, The investment management firm added 4,585 additional shares and now holds a total of 7,188 shares of Gilead Sciences which is valued at $571,230. Gilead Sciences makes up approx 0.06% of 1st Source Bank’s portfolio.Joel Isaacson boosted its stake in GILD in the latest quarter, The investment management firm added 226 additional shares and now holds a total of 1,310 shares of Gilead Sciences which is valued at $113,381. Gilead Sciences makes up approx 0.02% of Joel Isaacson’s portfolio.

Gilead Sciences closed down -0.01 points or -0.01% at $79.65 with 74,64,775 shares getting traded on Monday. Post opening the session at $79.88, the shares hit an intraday low of $79.43 and an intraday high of $80.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.